926 press releases were issued in the past 24 hours, and 184,430 press releases were issued in the past 365 days.
Non-small cell lung cancer treatment market
The early symptoms of lung cancer cannot be recognized because they are similar to other diseases such as pneumonia or collapsed lungs.
Seattle, Washington, USA, December 14, 2021 /EINPresswire.com/-Market Overview
The exact cause of non-small cell lung cancer has not been determined by a doctor, but air pollution, exposure to minerals and metal dust, smoking, and radiation therapy to the chest or breast are considered common causes. The early symptoms of lung cancer cannot be recognized because they are similar to other diseases such as pneumonia or collapsed lungs. Some common symptoms of lung cancer include chest pain, harsh/piercing sounds when breathing, wheezing, weight loss, constant coughing, hoarseness or changes in voice, shortness of breath, and lung problems such as bronchitis or pneumonia. In addition, if it spreads to other parts of the body through the blood or lymphatic vessels, symptoms such as bone pain, weakness in the arms or legs, yellow skin, yellow eyes, headaches and seizures may occur.
Get sample report through Covid19 analysis@ https://www.coherentmarketinsights.com/insight/request-sample/241
Usually, doctors will perform some diagnostic tests, including CT scans, X-rays, MRI, ultrasound, and PET scans. Lung cancer can also be diagnosed by biopsy, bronchoscopy, bronchoscopy, and mediastinoscopy.
The global non-small cell lung cancer treatment market in 2019 is estimated to be worth 19.161.7 billion U.S. dollars and is expected to grow at a compound annual growth rate of 9.3% during the forecast period (2019-2027).
It is expected that during the forecast period, increasing drug approvals will drive the growth of the global non-small cell lung cancer market. Major companies participate in research and development activities to obtain regulatory approvals. In May 2019, the EMA’s Committee on Medicinal Products for Human Use (CHMP) provided a positive opinion on Pfizer’s LORVIQUA drug, which is suitable for adult patients with ALK-positive advanced non-small cell lung cancer who have previously received alectinib Or Ceritinib as the first anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) therapy.
Buy now to enjoy a discount of 25-30% until December 31, 2021
Buy this advanced report at a discounted price @ https://www.coherentmarketinsights.com/insight/buy-now/241
For example, Roche Holdings obtained Rozlytrek (entrectinib) approved by the U.S. Food and Drug Administration (FDA) in August 2019, which is suitable for the treatment of adult ROS1-positive, metastatic non-small cell lung cancer. In addition, in May 2019, Pfizer obtained marketing authorization from the European Commission (EC) for LORVIQUA, a monotherapy for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) drug.
During the forecast period, high drug costs are expected to inhibit the growth of the global non-small cell lung cancer market. For example, in 2017, according to the Journal of Lung Cancer and Oncology, the total cost associated with lung cancer treatment in the United States was approximately US$13.9 billion, of which approximately 43% (US$6 billion) of costs occurred in initial treatment and 41% (US$5.8 billion) occurred In the last year of life. The price of medicines has risen over time, and this has been observed in medicines covered by outpatient prescription drug benefits. The prices of these drugs range from US$2,293/month in 2010 to US$14,079/month in 2017.
Among the regions, North America is expected to account for the largest share of the global non-small cell lung cancer market during the forecast period. This is because more and more non-small cell lung cancer drugs are approved. For example, in April 2018, AstraZeneca Pharmaceuticals LP’s Tagrisso (osimertinib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have Epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R mutation. The drug was approved by Health Canada in July 2018.
Due to the rising prevalence of lung cancer, strong growth is expected in the Asia-Pacific region. For example, according to the 2018 report of the Cancer Control and Information Service Center, approximately 125,100 lung cancer cases were reported in Japan in 2018.
The major companies participating in the global non-small cell lung cancer market are Pfizer, AstraZeneca, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GmbH, Novartis, Bristol-Myers Squibb and Merck & Co. Co., Inc.
Request a PDF manual of the latest insights here @ https://www.coherentmarketinsights.com/insight/request-pdf/241
Chapter 1 Industry Overview 1.1 Definition 1.2 Hypothesis 1.3 Research Scope 1.4 Market Analysis by Region 1.5 Market Size Analysis from 2021 to 2027 11.6 COVID-19 Outbreak: Impact of Non-Small Cell Lung Cancer Treatment Industry
Chapter 2 Non-Small Cell Lung Cancer Treatment Competition by Type, Application, and Top Regions and Countries 2.1 Market by Type (Volume and Value) 2.3 Market by Region (Volume and Value)
Chapter 3 Production Market Analysis 3.1 Global Production Market Analysis 3.2 Regional Production Market Analysis
Chapter 4 Non-small cell lung cancer treatment sales, consumption, export, import by region (2016-2021) Chapter 5 North American industry market analysis Chapter 6 East Asia non-small cell lung cancer treatment market analysis Chapter 7 European industry market analysis Chapter 8 South Asian non-small cell lung cancer treatment market analysis Chapter 9 Southeast Asian market analysis Chapter 10 Middle East non-small cell lung cancer treatment market analysis Chapter 11 African market analysis Chapter 12 Oceania market analysis Chapter 13 South America non-small cell lung cancer cancer treatment Market analysis Chapter 14 Company profile and key data of non-small cell lung cancer treatment business Chapter 15 Non-small cell lung cancer treatment market forecast (2021-2027) Chapter 16 Conclusion Research methods continue...
Do you have specific requirements? Consult our experts: https://www.coherentmarketinsights.com/insight/talk-to-analyst/241
Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, US Email: sales@coherentmarketinsights.com United States: +1-206-701-6702 United Kingdom: +44-020-8133-4027 Japan: +050 -5539- 1737 India: +91-848-285-0837
Mr. Shah Coherent Market Insights Pvt. Ltd. +1 206-701-6702 Email us here Visit us on social media: Facebook Twitter LinkedIn Other
EIN Presswire's top priority is source transparency. We do not allow non-transparent clients, and our editors will try to carefully eliminate false and misleading content. As a user, if you see something we have missed, please make sure to let us pay attention. Your help is welcome. EIN Presswire, or Everyone's Internet News Presswire™, tries to define some reasonable boundaries in today's world. Please refer to our editorial guide for more information.
© 1995-2021 IPD Group, Inc. dba EIN Presswire All rights reserved.